Monday, July 23, 2018
 
 
Company News: Page (1) of 1 - 07/11/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
CLASS ACTION UPDATE for MD and SYMC: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

(July 11, 2018)

NEW YORK, July 11, 2018 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court; further details about the cases can be found at the links provided.

MEDNAX, Inc. (NYSE:MD)

Class Period: February 4, 2016 – July 27, 2017Lead Plaintiff Deadline: September 10, 2018

The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) the Company's business model was not sustainable; and (2) Mednax's growth was in fact based upon suppressing physician compensation and enforcing non-compete agreements to deter physician defections.

On April 20, 2017, Mednax announced negative financial results for the first quarter of 2017. Then on July 28, 2017, during an earnings call, Mednax announced that the Company failed to complete any acquisitions of anesthesiologist practices during the second quarter and disclosed that any future acquisitions were unlikely. Following this news, shares of Mednax fell from a close of $56.49 on July 27, 2017, to a close of $47.73 per share the following day.

To learn more about the MD action go to: http://www.zlk.com/pslra-d/mednax-inc?wire=3.

Symantec Corp. (NASDAQ:SYMC)


Class Period: May 20, 2017 - May 10, 2018
Lead Plaintiff Deadline: July 16, 2018

The complaint alleges that Symantec's internal controls over financial reporting were materially weak and deficient; Symantec's later disclosed "reporting of certain Non-GAAP measures including those that could impact executive compensation programs" would lead to heightened regulatory scrutiny by the SEC; and as a result, Symantec's public statements were materially false and misleading at all relevant times. On May 10, 2018, Symantec announced the commencement of an internal investigation “in connection with concerns raised by a former employee.”

To learn more about the SYMC action go to: http://www.zlk.com/pslra-d/symantec-corp?wire=3.

You have until the lead plaintiff deadlines to request the court appoint as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com


Page: 1


Related Keywords:
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • Healthcare IT Market 2018 - 2023 with SWOT Analysis regarding upcoming Changes and Technology Adaptations in Global Healthcare Sector
  • Sciatica Market Research Valued 18.9 Billion US$ by 2023: A Comprehensive Sciatica Market Growth by by type, by Drug Treatment and by End User
  • Medical Sensors Market to be Worth US$18.74 Billion by 2023, Says TMR
  • Vision Care Product Market To Witness Enhanced Growth Owing To Rising Occurrence Of Eye Disorders Till 2021 | Million Insights
  • Global Prosthetic Heart Valve Market Reaching at a CAGR of +12.70% by Geography, Deployment Model, Component, and Key players are Boston Scientific Cardiology, CryoLife, Inc., Abbott

    Cancer
  • CStone Pharmaceuticals Appoints Former Goldman Sachs Executive Richard Yeh as CFO
  • Immune Advisors Publishes Peer-Reviewed Study Demonstrating Efficacy of a Probiotic and Digestive Enzymes Supplement in Protecting Against Side Effects of Cancer Chemotherapy
  • CytRx Corporation Announces Expiration of Outstanding Warrants
  • HedgePath Pharmaceuticals Granted Exclusive Option to License UCONN's Patented Chemical Analogues of Itraconazole
  • Alligator Bioscience Submits Application to Start Clinical Phase I Study in Cancer Patients with ATOR-1015, a Unique CTLA-4 and OX40 Binding Antibody
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines